Online inquiry

IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8024MR)

This product GTTS-WQ8024MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD52 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001803.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1043
UniProt ID P31358
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD52, GZ-402668(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8024MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3540MR IVTScrip™ mRNA-Anti-MIF, BAX069(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BAX069
GTTS-WQ12296MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ324MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ15665MR IVTScrip™ mRNA-Anti-EPCAM, VB6-845(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VB6-845
GTTS-WQ7177MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ12119MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ2636MR IVTScrip™ mRNA-Anti-IL2RB, AMG 592(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA AMG 592
GTTS-WQ5943MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW